At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
Rising drug prices in the US are hot topic. Inbeeo takes a look at the recent drug pricing proposal by the Democrats suggesting the use of ERP.
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
Inbeeo’s analysis of 2018 drug pricing tweets using NLP machine learning techniques highlight how emotive the issue of pharmaceutical pricing really is.
What is Value-Based Pricing? It’s pricing based on value! Or is it? Let us try to define what it is once and for all.
France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
The event that made people pay attention to how prescription drugs are being priced
The value-denial syndrome used to be broadly shared between payers and the industry, and now they both seem to come to the same realization that value-based pricing is the only way. Easier said than done, but that’s a start.
The Health Foundation and ICHOM are among the many stakeholders calling for an evolution of how we look at value in healthcare. Here are four trends emerging from their pledge.
Five tips worth keeping mind when planning for market access. An infographic.
I have learned the hard way that defining the value of a pharmaceutical innovation is not as easy as “Bob’s your uncle”.
A Care Affordability Index could constitute a way more informative measure of patient-access performance than the binary “number of lives covered”. And it is not that complicated to implement. A post for dashboard lovers.
Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.
Making sure your new product brings no bad budgetary news, clearly telling its value story, and pricing it fairly will help you convince your payer audience to fund it.
As pharma industry leaders continue to feel a pressuring demand from all parts to justify the price of their innovative products, there is one trap everyone seems to be happily falling into – the cost of Research and Development.